- La Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products.
- Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring.
- With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Our Take On La Jolla Pharmaceutical Company